GERN GERON CORP
Pharmaceutical Preparations · Nasdaq · SEC CIK 886744 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY40.2%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-20.1%
ROA-8.7%
ROIC (approx.)-8.9%
Asset turnover—
Leverage & solvency
Liabilities / assets57.0%
Debt / equity0.53x
Current ratio6.31x
Interest coverage-1.11x
Cash quality & payout
Operating cash flow / net income1.89x
Accruals ratio7.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $71.43M | $103.74M |
| SG&A expense | $159.26M | $145.73M |
| Operating income | -$68.58M | -$173.73M |
| Interest expense | $32.66M | $18.50M |
| Pretax income | -$83.42M | -$174.52M |
| Income tax | $75,000 | $449,000 |
| Net income | -$83.50M | -$174.57M |
| EBITDA | -$68.11M | -$173.19M |
| EPS (basic) | -0.13 | -0.27 |
| EPS (diluted) | -0.13 | -0.27 |
| Weighted avg. shares (diluted) | 666.66M | 646.03M |
| Balance sheet | ||
| Cash & equivalents | $77.56M | $79.02M |
| Short-term investments | — | $327.55M |
| Receivables | $36.99M | $35.95M |
| Inventory | $116.64M | $38.71M |
| Current assets | $520.27M | $490.99M |
| PP&E, net | $884,000 | $1.31M |
| Total assets | $570.54M | $593.78M |
| Current liabilities | $111.54M | $88.30M |
| Short-term debt | — | $0 |
| Long-term debt | $119.55M | $118.48M |
| Total debt | $119.55M | $118.48M |
| Total liabilities | $344.67M | $313.46M |
| Shareholders' equity | $225.87M | $280.32M |
| Net debt | $41.99M | $39.46M |
| Shares outstanding | 639.86M | 606.39M |
| Cash flow statement | ||
| Operating cash flow | -$111.04M | -$218.62M |
| Capital expenditure | — | $680,000 |
| Free cash flow | — | -$219.30M |
| Investing cash flow | $107.25M | -$106.00M |
| Financing cash flow | $2.27M | $334.37M |
| Depreciation & amortization | $474,000 | $546,000 |
| Stock-based compensation | $26.66M | $31.18M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.